Coronavirus Live Count Map India
remove_red_eye 632 Views
Coronavirus Live Count Map World
#Allergy and Immunology #Cardiology #Gastroenterology #General Surgery #Pharmacist
The JAK-1 inhibitor upadacitinib was found to be superior to placebo in inducing endoscopic remission in refractory Crohns disease (CD) patients in the phase II randomized CELEST trial.
Investigators reported that while no placebo patients achieved endoscopic remission, patients across different treatment dose groups did so. Rates of clinical remission were as follows among dosage groups: 13% of those receiving 3 mg of upadacitinib twice daily; 27% of those receiving 6 mg of upadacitinib twice daily; 11% of those receiving 12 mg twice daily; 22% of those receiving 24 mg twice daily; 14% of those receiving 24 mg once daily; 11% of those receiving placebo. The findings were published online in Gastroenterology.